Varenicline: The Newest Agent for Smoking Cessation

Lisa A. Potts; Candice L. Garwood

Am J Health Syst Pharm. 2007;64(13):1381-1384.

Conclusion

Varenicline, a newly approved agent for smoking cessation, offers a new option to patients who cannot tolerate the adverse effects associated with NRT and bupropion. It is also an alternative to consider in patients with contraindications to such therapies.

1 2 3 4 5 6 7 8 9

Next Section

Reprint Address

Lisa A. Potts, Department of Pharmacy, Cleveland Clinic, 9500 Euclid Avenue (W20), Cleveland, OH 44195. E-mail: pottsl@ccf.org .

Cite this: Varenicline: The Newest Agent for Smoking Cessation - Medscape - Jul 01, 2007.

Table 1. Cost Comparison of Currently Available Smoking-Cessation Therapies
Drug	Cost ($)/30-Day Supply^a	Availability Status
Varenicline	106.99	Prescription
Bupropion	69.98	Prescription
Nicotine patch	120	Nonprescription
Nicotine gum	46.61-50.43 (108 pieces)	Nonprescription
Nicotine nasal spray	99.97 (3 bottles)	Prescription
Nicotine inhaler	136.99	Prescription
Nicotine lozenge	56.99 (108 pieces)	Nonprescription

^aPrices obtained from www.drugstore.com in November 2006.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Varenicline: The Newest Agent for Smoking Cessation

Conclusion

Tables

References

Authors and Disclosures

Authors and Disclosures

Comments

Email This

Feedback